Evidence map›Paper›PMID 41767498›Full record

ArticleFrontiers in medicine2026

Development and validation of a CT-based habitat radiomics model for predicting pathological grading in non-small cell lung cancer.

Dexuan Xie, Chongyang Sun, Ming Xue, Xigang Xiao

Abstract read
In one paragraph

Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Dexuan XieDepartment of Radiology, First Affiliated Hospital of Harbin Medical University, Harbin, China.
Chongyang SunDepartment of Radiology, First Affiliated Hospital of Harbin Medical University, Harbin, China.
Ming XueDepartment of Radiology, First Affiliated Hospital of Harbin Medical University, Harbin, China.
Xigang XiaoDepartment of Radiology, First Affiliated Hospital of Harbin Medical University, Harbin, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: To develop and validate models for predicting pathological grading of non-small cell lung cancer (NSCLC) using habitat radiomics and clinical semantic features. Materials and methods: In this retrospective study of 800 NSCLC patients, a whole tumor volume (WTV) was delineated by applying a 3 mm expansion to the gross tumor volume (GTV) on non-contrast CT scans. Habitat subregions within the WTV were identified using K-means clustering. A two-step binary classification model was constructed to predict pathological grades: Model-1 distinguished Grade 3 from combined Grades 1-2, and Model-2 further differentiated Grade 1 from Grade 2. Predictive models were built with logistic regression based on four distinct feature sets: WTV radiomics (Clf WVOI), habitat radiomics (Clf Habitats), clinical features (Clf Clinical), and a combined feature set (Clf Total). Results: In both Model-1 and Model-2, the classification performance of Clf Habitats was generally superior to that of Clf WVOI and Clf Clinical, achieving an AUC of 0.89 and 0.87, specificity of 0.73 for both models, and BACC of 0.78 and 0.79, respectively, on the test set. The combined model, Clf Total, achieved the best predictive performance on the test set, with AUC values of 0.91 and 0.88, specificity of 0.84 and 0.77, and BACC of 0.82 and 0.81. Conclusion: Habitat radiomics significantly improves NSCLC pathological grading. The multimodal model offers robust performance and high specificity, aiding personalized treatment planning.

Indexed as

computed tomographygradinghabitatnon-small cell lung cancerradiomics

Identifiers

PMID41767498
PMCPMC12936033

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.